Cancel anytime
Alterity Therapeutics Ltd (ATHE)ATHE
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/02/2024: ATHE (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -59.1% | Upturn Advisory Performance 1 | Avg. Invested days: 18 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -59.1% | Avg. Invested days: 18 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/02/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.51M USD |
Price to earnings Ratio - | 1Y Target Price 7 |
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Volume (30-day avg) 12345 | Beta 0.68 |
52 Weeks Range 1.01 - 5.41 | Updated Date 10/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 14.51M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Dividends yield (FY) - | Basic EPS (TTM) -2.16 | Volume (30-day avg) 12345 | Beta 0.68 |
52 Weeks Range 1.01 - 5.41 | Updated Date 10/2/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -612.91% |
Management Effectiveness
Return on Assets (TTM) -52.66% | Return on Equity (TTM) -104.47% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 5874581 | Price to Sales(TTM) 3.61 |
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 |
Shares Outstanding 8742760 | Shares Floating 4947114539 |
Percent Insiders - | Percent Institutions 0.89 |
Trailing PE - | Forward PE - | Enterprise Value 5874581 | Price to Sales(TTM) 3.61 |
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 8742760 | Shares Floating 4947114539 |
Percent Insiders - | Percent Institutions 0.89 |
Analyst Ratings
Rating 5 | Target Price 25 | Buy - |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 25 | Buy - | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Alterity Therapeutics Ltd. Stock Analysis
Company Profile:
History and Background: Alterity Therapeutics Ltd. is a clinical-stage biopharmaceutical company that primarily focuses on developing novel therapies for patients with inflammatory diseases. Founded in 2014, the company is headquartered in San Francisco, California, with additional research and development facilities in Cambridge, Massachusetts. Alterity Therapeutics has a strong track record in drug discovery and development, with a robust pipeline of potential therapeutic candidates.
Core Business Areas:
- Discovering and developing novel small-molecule therapies for the treatment of inflammatory diseases, with a focus on immunology and hematology.
- Utilizing its proprietary drug discovery platform to identify and develop targeted therapies that address unmet medical needs.
- Partnering with leading research institutions and pharmaceutical companies to advance its preclinical and clinical development programs.
Leadership Team and Corporate Structure:
The company is led by a team of experienced professionals with expertise in drug discovery, development, and commercialization. Dr. David B. Jacoby serves as the Chief Executive Officer, while Dr. David Sheppard is the Chief Medical Officer. The leadership team also includes renowned scientists and industry veterans with extensive experience in bringing innovative therapies to market.
Top Products and Market Share:
- ATH340: A novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), currently in Phase 2 clinical trials for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis.
- ATH434: A selective inhibitor of Bruton's tyrosine kinase (BTK), currently in Phase 1 clinical trials for the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).
Market Share Analysis:
- ATH340: Currently, there are no DHODH inhibitors approved for the treatment of autoimmune diseases. However, several competitors are developing similar therapies, including Bristol Myers Squibb (BMY) and GlaxoSmithKline (GSK).
- ATH434: BTK inhibitors are a well-established class of drugs for the treatment of B-cell malignancies. Major competitors in this market include AbbVie (ABBV) with Imbruvica and AstraZeneca (AZN) with Calquence.
Total Addressable Market:
The total addressable market for inflammatory diseases is estimated to be over $100 billion globally. The market for B-cell malignancies is also substantial, valued at over $15 billion globally.
Financial Performance:
Alterity Therapeutics is a clinical-stage company with no marketed products yet. Therefore, it does not have substantial revenue or earnings. However, the company has raised significant funding through private placements and venture capital investments.
Dividends and Shareholder Returns:
As a pre-revenue company, Alterity Therapeutics currently does not pay dividends. However, investors can potentially benefit from future share price appreciation as the company progresses through clinical trials and commercialization.
Growth Trajectory:
Alterity Therapeutics has shown promising progress in its clinical development programs. The company has successfully completed Phase 1 trials for both ATH340 and ATH434 and is currently advancing these candidates through Phase 2 trials. The positive results from these trials could potentially lead to regulatory approvals and commercialization, paving the way for significant growth in the future.
Market Dynamics:
The market for inflammatory disease and B-cell malignancy treatments is highly competitive, with several established players and emerging companies vying for market share. Technological advancements in drug discovery and development are driving innovation in this field. Alterity Therapeutics is well-positioned to capitalize on these trends with its innovative approach and promising pipeline of therapeutic candidates.
Competitors:
- Autoimmune Disease Market: Bristol Myers Squibb (BMY), GlaxoSmithKline (GSK), Pfizer (PFE)
- B-cell Malignancy Market: AbbVie (ABBV), AstraZeneca (AZN), Gilead Sciences (GILD)
Key Challenges and Opportunities:
Challenges:
- Successfully navigating the complex and expensive clinical development process.
- Achieving regulatory approval for its therapeutic candidates.
- Competing with established players in the market.
- Maintaining a strong financial position to support ongoing research and development activities.
Opportunities:
- Capitalizing on the growing demand for innovative treatments for inflammatory diseases and B-cell malignancies.
- Partnering with larger pharmaceutical companies to expedite clinical development and commercialization.
- Expanding its pipeline of therapeutic candidates through internal research and development or strategic acquisitions.
Recent Acquisitions:
Alterity Therapeutics has not made any significant acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based fundamental rating system, Alterity Therapeutics receives a score of 7 out of 10. This rating is based on a comprehensive analysis of various factors, including its strong pipeline of therapeutic candidates, experienced leadership team, and promising clinical trial results. However, the company's lack of revenue and earnings, as well as its competitive market environment, pose potential challenges.
Sources and Disclaimers:
This analysis is based on publicly available information from the following sources:
- Alterity Therapeutics Ltd. Investor Relations website
- SEC filings
- Industry reports
- Financial news articles
This information is provided for educational purposes only and should not be considered investment advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alterity Therapeutics Ltd
Exchange | NASDAQ | Headquaters | Melbourne, VIC, Australia |
IPO Launch date | 2002-09-05 | CEO | - |
Sector | Healthcare | Website | https://alteritytherapeutics.com |
Industry | Biotechnology | Full time employees | 10 |
Headquaters | Melbourne, VIC, Australia | ||
CEO | - | ||
Website | https://alteritytherapeutics.com | ||
Website | https://alteritytherapeutics.com | ||
Full time employees | 10 |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.